#161752

DLKP-A10 cell line

Cat. #161752

DLKP-A10 cell line

Cat. #: 161752

Organism: Human

Tissue: Lung

Disease: Cancer

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Martin Clynes

Institute: Dublin City University

Primary Citation: Clary et. al. Biochemical Pharmacology, 1997 53(10): 1493-1502. PMID: 9260877

Tool Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: DLKP-A10 cell line
  • Parental cell: DLKP cell line
  • Organism: Human
  • Tissue: Lung
  • Disease: Cancer
  • Morphology: Monolayer
  • Crispr: No
  • Products or characteristics of interest: The cell line exhibits various levels of resistance to chemotherapeutic agents
  • Description: DLKP-A10 is a drug-resistant subpopulation of DLKP squamous carcinoma cell line. It overexpresses the MDR associated P-glycoprotein efflux pump.
  • Production details: DLKP-A was established by continuous exposure of the DLKP cells (pDLKP) to escalating concentrations of Adr (Step 1: 0.05 ?g/mL–0.8 ?g/mL Adr for 11 months, Step 2: 0.8 ?g/mL–1.75 ?g/mL for 3 months and Step 3: 1.75 ?g/mL–2.1 ?g/mL for 3 months)

Handling

  • Volume: Frozen
  • Growth medium: DMEM-F12 medium supplemented with 5% FBS and 1% L-glutamine
  • Temperature: 37° C
  • Atmosphere: 5% CO2
  • Shipping conditions: Dry ice
  • Storage conditions: Liquid Nitrogen
  • Mycoplasma free: Yes

References

  • Clary et. al. Biochemical Pharmacology, 1997 53(10): 1493-1502. PMID: 9260877
  • Efeoglu et. al. Biomolecules. 2022 Oct 1,12(10):1401. PMID: 36291610